Monocentric, randomised, double-blind, placebo-controlled pilot study in double-dummy design in overweight or obese patients to compare two treatment regimes (Polyglucosamine L112 vs. Orlistat 60 mg)
Phase of Trial: Phase III
Latest Information Update: 13 Jan 2014
At a glance
- Drugs Orlistat; Polyglucosamine L112
- Indications Obesity; Overweight
- Focus Registrational; Therapeutic Use
- Sponsors Certmedica International
- 02 Jun 2012 Planned number of patients changed from 40 to 60 as reported by European Clinical Trials Database.
- 02 Jun 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-001692-30).
- 07 Sep 2011 New trial record